Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial

NCT01926496 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT01926496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01926496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial
Lead sponsor
LEO Pharma
Phase
Phase 4
Overall status
Completed
Start date
September 11, 2013
Completion date
July 11, 2019
Enrollment
485 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis (ak)